Systemic sclerosis (scleroderma): remaining challenges

Despite progress in treating internal organ involvement in systemic sclerosis (scleroderma) (SSc), such as pulmonary disease, effective treatments for the hallmark of the disease, cutaneous fibrosis, remain elusive. None of the disease-modifying antirheumatic drugs (DMARDS) have shown proven efficac...

Descripción completa

Detalles Bibliográficos
Autor principal: Connolly, Mary Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Rheumatologic Skin Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033370/
https://www.ncbi.nlm.nih.gov/pubmed/33842659
http://dx.doi.org/10.21037/atm-20-5449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033370/
https://www.ncbi.nlm.nih.gov/pubmed/33842659
http://dx.doi.org/10.21037/atm-20-5449

Ejemplares similares